CD80
离子霉素
CD86
佐剂
T细胞
免疫系统
化学
流式细胞术
树突状细胞
CD8型
体内
分子生物学
体外
药理学
免疫学
生物
细胞毒性T细胞
生物化学
CD40
生物技术
作者
Nilgün Yakuboğulları,Ali Çağır,Erdal Bedir,Duygu Sag
出处
期刊:Vaccines
[MDPI AG]
日期:2023-02-21
卷期号:11 (3): 495-495
被引量:1
标识
DOI:10.3390/vaccines11030495
摘要
Astragaloside VII (AST VII), a triterpenic saponin isolated from Astragalus species, shows promise as a vaccine adjuvant, as it supported a balanced Th1/Th2 immune response in previous in vivo studies. However, the underlying mechanisms of its adjuvant activity have not been defined. Here, we investigated the impact of AST VII and its newly synthesized semi-synthetic analogs on human whole blood cells, as well as on mouse bone marrow-derived dendritic cells (BMDCs). Cells were stimulated with AST VII and its derivatives in the presence or absence of LPS or PMA/ionomycin and the secretion of cytokines and the expression of activation markers were analyzed using ELISA and flow cytometry, respectively. AST VII and its analogs increased the production of IL-1β in PMA/ionomycin-stimulated human whole blood cells. In LPS-treated mouse BMDCs, AST VII increased the production of IL-1β and IL-12, and the expression of MHC II, CD86, and CD80. In mixed leukocyte reaction, AST VII and derivatives increased the expression of the activation marker CD44 on mouse CD4+ and CD8+ T cells. In conclusion, AST VII and its derivatives strengthen pro-inflammatory responses and support dendritic cell maturation and T cell activation in vitro. Our results provide insights into the mechanisms of the adjuvant activities of AST VII and its analogs, which will be instrumental to improve their utility as a vaccine adjuvant.
科研通智能强力驱动
Strongly Powered by AbleSci AI